Drug-Eluting Vascular Stent System

Restenosis in the SFA

A harsh SFA environment
Significant mechanical forces in the SFA prolong the response to injury and make the SFA susceptible to restenosis.

Sustained drug release to reduce restenosis

It’s the science behind the unique design of the Eluvia™ Drug-Eluting Stent that explains its unparalleled primary patency and TLR rates. Before developing Eluvia, our scientists sought to fully understand the restenotic process, and the recognition that restenosis peaks at 12 months post implantation1 became fundamental to the Eluvia DES design.


Restenosis following nitinol stenting in the SFA peaks at ~12 months1

Clinical History of Restenosis
Eluvia™ was developed to counter this peak in the restenotic cascade – and is the only drug-eluting stent to offer a sustained release of paclitaxel (PTX) that extends to the critical 12-month timepoint. While other DES may only elute PTX for 2-3 months, Eluvia continues to fight restenosis when the risk is at its highest.

The Eluvia™ stent system was designed to sustain drug release when restenosis is most likely to occur.1

*Based on pre-clinical PK analysis. Data on file at Boston Scientific. Dake MD, et al. J Vasc Interv Radiol. 2011;22(5):603-610.


Eluvia has the lowest drug dose density of any PTX therapy2

Eluvia DES